U.S. Cancer Statistics Prostate Cancer Stat Bite

In the United States in 2019—

• 224,733 new prostate cancers were reported.
• 31,636 males died from prostate cancer.

Males had much higher rates of getting prostate cancer than dying from prostate cancer.

Stage Distribution

From 2015 to 2019, about 71% of prostate cancer cases were diagnosed at a localized stage, meaning the cancer had not spread outside the prostate. 14% of prostate cancers were found at a regional stage (the cancer had spread to nearby lymph nodes, tissues, or organs), and 8% were found at a distant stage (the cancer had spread to distant parts of the body).

5-Year Relative Survival

96% of prostate cancer patients who were diagnosed from 2012 to 2018 had not died from their cancer 5 years later.

Survival is high because many prostate cancers grow slowly or not at all. The goal of screening for prostate cancer is to find cancers that may grow if not treated. Men and their doctors should talk about the possible harms and benefits of screening.

Data Sources

Data are from U.S. Cancer Statistics, the official federal cancer statistics.

U.S. Cancer Statistics incidence data are from population-based registries that participate in CDC’s National Program of Cancer Registries (NPCR), the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, or both programs and met high-quality data criteria for the 2021 data submission, covering 99% of the U.S. population.

U.S. Cancer Statistics death data are from CDC’s National Center for Health Statistics National Vital Statistics System and cover 100% of the U.S. population.

U.S. Cancer Statistics survival and prevalence data are from 42 NPCR registries that met high-quality data criteria for the 2021 data submission and linked the National Death Index, conducted active patient follow-up, or performed both of these activities. The resulting data cover 88% of the U.S. population. Five-year relative survival estimates are based on cases diagnosed from 2012 to 2018. Five-year limited-duration prevalence estimates are based on cases diagnosed from 2014 to 2018.